Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 10, 2022Open Access

Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMarlou J. JongkeesDGDaryl GeersKHKathryn S. Hensley

Discussion

Loading...

Member takes

Overview

Prospective study demonstrates an additional mRNA-1273 dose induces robust antibody responses in people living with HIV with initial hyporesponse, indicating successful immune rescue.

Key Points

  • To determine whether an additional 100 µg dose of mRNA-1273 boosts humoral and cellular immune responses in people living with HIV (PLWH) who had a hyporesponse after a primary SARS-CoV-2 vaccination regimen.
  • Prospective interventional study evaluating 66 consenting PLWH with antibody levels ≤300 BAU/mL following primary vaccination with ChAdOx1-S (n=40), BNT162b2 (n=22), or Ad26.COV2.S (n=4).
  • Participants received an additional 100 µg mRNA-1273 vaccination, with antibody levels, neutralizing capacity, and spike-specific T- and B-cell responses assessed 28 days post-vaccination.
  • Binding antibodies exceeded 300 BAU/mL in 64 of 66 participants (97%) at day 28, with a mean increase of 4282 BAU/mL (95% CI: 3241 to 5323).
  • The additional vaccination significantly increased the proportion of participants with detectable ancestral spike-specific B-cells (p=0.016) and CD4+ T-cells (p=0.037).
  • Neither baseline patient characteristics (including CD4+ nadir and viral suppression) nor the primary vaccine regimen correlated with the magnitude of the antibody response.

Cite This Study

Jongkees et al. (2022) studied this question.

synapsesocial.com/papers/6aa2fbc50168768c14c07a8fhttps://doi.org/10.1101/2022.08.10.22278577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands2022 · 8 citations
  2. 2Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation2017 · 280 citations
  3. 3Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant2022 · 114 citations
  4. 4People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses2022 · 20 citations
  5. 5Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial2021 · 162 citations